-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Eli Lilly recently announced that the US Food and Drug Administration (FDA) has approved the rapid-acting insulin product Lyumjev® (insulin lispro-aabc injection) 100 units/ml label extension to include: through an insulin pump Continuous subcutaneous insulin infusion (CSII) is administered to improve blood glucose control in adults with type 1 and type 2 diabetes
Lyumjev is a new insulin lispro preparation designed to accelerate the absorption of insulin into the blood and reduce A1C levels.
This approval is based on the results of the PRONTO-PUMP-2 study
Lyumjev is available in the United States and several global markets, including Japan and the European Union, where the product is also approved for use in insulin pumps
Note: The original text has been deleted
Original source: FDA approves Lyumjev® (insulin lispro-aabc injection) 100 units/mL for use in insulin pumps